ClinicalTrials.gg
RecruitingNCT04968808Updated Jul 28, 2026

Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)

An interventional study of Staged in-hospital complete revascularization and Immediate complete revascularization in Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis and Multi Vessel Coronary Artery Disease, sponsored by Chonnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,014
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.

Planned enrollment
4th of 11
1,014 · median 860
Started
2021
with 2 others
No phase
9 of 12
6 open now
Registered
6th of 12
by date

Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 6th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Myocardial Infarction by Chonnam National University Hospital, or all of them as a file.
02

Study summary

Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (percutaneous coronary intervention [PCI] for both infarct-related artery [IRA] and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of fractional flow reserve (FFR), and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.

Read the detailed description

Many patients with non-ST-segment elevation myocardial infarction (NSTEMI) have multivessel coronary artery disease (MVD), which is associated with poor clinical outcomes. In cases of hemodynamically stable ST-segment elevation myocardial infarction (STEMI) and MVD, many studies demonstrated the superiority of complete revascularization (CR) by both one-stage and multistage procedures compared to culprit-only revascularization (COR). The 2017 European Society of Cardiology (ESC) guidelines for STEMI recommend routine revascularization for non infarct-related artery (IRA) lesions before hospital discharge in patients without cardiogenic shock.

However, there have been few studies regarding revascularization strategy in patients with NSTEMI and MVD. Only one randomized controlled trial, the SMILE trial (J Am Coll Cardiol 2016;67:264-72), compared one-stage and multi-stage multivessel revascularization (MVR) in these patients. Although the results of most studies analyzing interventional strategies in patients with NSTEMI and MVD showed superior results of MVR compared to COR, they did not provide information about staged revascularization. One-stage MVR was associated with better clinical outcomes compared to multi-stage MVR in the SMILE trial, while one-stage and multi-stage MVR had similar incidences of adverse outcomes in large registry data. Although the 2018 ESC/European Association for Cardio-Thoracic Surgery (EACTS) guidelines for myocardial revascularization recommend complete one-stage revascularization in NSTEMI and MVD, it emphasizes individualization based on clinical status and comorbidities, as well as disease severity. In 2020 ESC guidelines for non-ST-segment elevation acute coronary syndrome, this strategy is maintained. CR during index percutaneous coronary intervention (PCI) is recommended in NSTEMI patients with MVD (class IIb, level B).

Whether to revascularize non-IRA using angiography or fractional flow reserve (FFR) is also problematic. FFR is a useful tool for assessing hemodynamic significance of non-IRA during both acute and subacute stage, and FFR-guided PCI for non-IRA lesion is recommended during index PCI (class IIb, level B). In the SMILE trial, a 25.8% of study patients received FFR-guided PCI for non-IRA. Although FFR is a well-known tool to evaluate significant ischemia of moderate stenosis, the most studies regarding FFR enrolled patients without acute myocardial infarction (AMI).

However, the recommendations in current guidelines, which recommends CR during index PCI, is not sufficiently powered to assess differences in clinical outcomes between interventional strategy. There are also few studies regarding this issue, and discrepancy in clinical outcomes between randomized trial and observational studies. Furthermore, FFR-guided PCI for non-IRA is not mandatory in these studies.

Therefore, we planned to perform prospective, open-label, randomized trial to evaluate the efficacy and safety of immediate complete revascularization (PCI for both IRA and non-IRA during index PCI) compared to staged PCI strategy of non-IRA (PCI for IRA followed by non-IRA PCI after several days). PCI procedure at non-IRA with diameter stenosis between 50 and 69% should be conducted with the aid of FFR, and non-IRA with diameter stenosis ≥ 70% will be revascularized without FFR.

03

Conditions studied

  • Myocardial Infarction, Acute
  • Multi-Vessel Coronary Artery Stenosis
  • Multi Vessel Coronary Artery Disease

Keywords

  • Non-ST-Segment Elevation Myocardial Infarction
  • Multi-Vessel Coronary Artery Disease
  • Multi-Vessel Coronary Artery Stenosis
  • Culprit-Only
  • Multi-Vessel Percutaneous Coronary Intervention
  • Percutaneous Coronary Intervention
  • Complete Revascularization
  • Timing
  • Staged Percutaneous Coronary Intervention
  • Fractional Flow Reserve
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 19 years old
  2. Non-ST-segment elevation myocardial infarction

    • Angina pectoris or equivalent ischemic chest discomfort with at least 1 of 3 features and,

      • occurs at rest, usually lasting > 10 minutes
      • severe and new onset (within the prior 4-6 weeks)
      • crescendo pattern
    • Elevated cardiac biomarkers and,

      • ≥ 99% value of high-sensitivity cardiac troponin
    • No ST-segment elevation ≥ 0.1 mV in ≥ 2 contiguous leads or newly developed left bundle branch block on 12-lead
  3. PCI within 72 hours after symptom development
  4. Multivessel disease: Non-IRA with at least 2.5 mm diameter and 50% diameter stenosis by visual estimation
  5. Patient's or protector's agreement about study design and the risk of PCI

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock at initial presentation or after treatment of IRA
  2. TIMI flow at non-IRA ≤ 2
  3. Severe procedural complications (e.g. persistent no-reflow phenomenon, coronary artery perforation) which restricts study enrollment by operators' decision
  4. Non-IRA lesion not suitable for PCI treatment by operators' decision
  5. Chronic total occlusion at non-IRA
  6. History of anaphylaxis to contrast agent
  7. Pregnancy and lactation
  8. \< 1-year
  9. Severe valvular disease
  10. History of CABG, or planned CABG
  11. Fibrinolysis before admission
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,014 participants (estimated)

Study arms

  • Active comparator
    Staged in-hospital CR (complete revascularization)

    Non-infarct related artery (IRA) will be revascularized in other day (during hospitalization) after percutaneous coronary intervention (PCI) for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

    Procedure: Staged in-hospital complete revascularization

  • Experimental
    Immediate CR (complete revascularization)

    Non-infarct related artery (IRA) will be revascularized immediately after percutaneous coronary intervention (PCI) for IRA (during index PCI). Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

    Procedure: Immediate complete revascularization

Interventions

  • ProcedureStaged in-hospital complete revascularization

    Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Staged in-hospital complete revascularization group will receive staged PCI for non-IRA in other day (during hospitalization) after PCI for IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

  • ProcedureImmediate complete revascularization

    Patients with non-ST-segment elevation myocardial infarction and multivessel disease will be randomized after percutaneous coronary intervention (PCI) for infarct-related artery (IRA). All patients will be randomized to immediate complete revascularization group or staged revascularization group by 1:1 fashion. Immediate complete revascularization group will receive simultaneous PCI for both IRA and non-IRA during index PCI. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without fractional flow reserve (FFR) evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion wll be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence rate of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization

    Composite endpoint of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization at 1 year from baseline

    Time frame: Up to 12 months

Secondary outcomes

  1. Rate of contrast-induced nephropathy

    Rate of contrast-induced nephropathy during initial hospitalization

    Time frame: Up to 12 months

  2. Cumulative incidence rate of all unplanned revascularization

    Cumulative incidence rate of all unplanned revascularization at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  3. Cumulative incidence rate of target-lesion revascularization

    Cumulative incidence rate of target-lesion revascularization at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  4. Cumulative incidence rate of target-vessel revascularization

    Cumulative incidence rate of target-vessel revascularization at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  5. Cumulative incidence rate of non-target vessel revascularization

    Cumulative incidence rate of non-target vessel revascularization at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  6. Cumulative incidence rate of all-cause death

    Cumulative incidence rate of all-cause death at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  7. Cumulative incidence rate of cardiac death

    Cumulative incidence rate of cardiac death at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  8. Cumulative incidence rate of non-cardiac death

    Cumulative incidence rate of non-cardiac death at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  9. Cumulative incidence rate of non-fatal myocardial infarction

    Cumulative incidence rate of non-fatal myocardial infarction at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  10. Cumulative incidence rate of hospitalization for unstable angina

    Cumulative incidence rate of hospitalization for unstable angina at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  11. Cumulative incidence rate of hospitalization for heart failure

    Cumulative incidence rate of hospitalization for heart failure at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  12. Cumulative incidence rate of definite or probable stent thrombosis

    Cumulative incidence rate of definite or probable stent thrombosis at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  13. Cumulative incidence rate of ischemic and hemorrhagic stroke

    Cumulative incidence rate of ischemic and hemorrhagic stroke at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  14. Cumulative incidence rate of major bleeding (BARC [Bleeding Academic Research Consortium] definitions type 3 or 5)

    Cumulative incidence rate of major bleeding (BARC \[Bleeding Academic Research Consortium\] definitions type 3 or 5) at each visit

    Time frame: Index admission, 1 month, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

  15. Cumulative incidence rate of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization

    Composite endpoint of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization at each visit

    Time frame: Index admission, 1 month, 6 months, 24 months, 36 months, 48 months, 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Aug 2028, 83 months after the start.

Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 83 months is above that.

Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2021
First posted
Jul 20, 2021
StartActual
Sep 6, 2021
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2032
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04968808
Lead sponsor
Chonnam National University Hospital
Responsible party
Min Chul Kim (Professor, Chonnam National University Hospital) — Principal investigator
First posted
Jul 20, 2021
Start date
Sep 6, 2021
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2032 (estimated)
Last update
Jul 28, 2026

Study contacts

Min Chul Kim, MD
Contact
kmc3242@hanmail.net
82-62-220-6578
Min Chul Kim, MD
principal investigator · Chonnam National University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion